EPA
REGN icon

Element Pointe Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Element Pointe Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,132
Closed -$791K – 83
2022
Q1 		$791K Sell
1,132
-419
-27% -$265K 0.27% 48
2021
Q4 		$979K Buy
1,551
+198
+15% +$122K 0.3% 56
2021
Q3 		$819K Buy
+1,353
New +$840K 0.28% 62

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Element Pointe Advisors's REGN Position: Q2 2022 in Review

Element Pointe Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 1,132 shares — an estimated $791K sold.

Element Pointe Advisors first reported a position in REGN in Q3 2021 and held it in 3 quarters. The position peaked at $979K in Q4 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Element Pointe Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Element Pointe Advisors sold 1,132 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $791K.
  • Element Pointe Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Element Pointe Advisors's Regeneron Pharmaceuticals position peaked at $979K in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Element Pointe Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.